TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

APHAIA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

APHAIA

ST13

US500000079387263

Class

5, 42

Filing

79387263

Registration

8006925

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

06/19/2026

Classification

Registered

Trademark type

Word

Nice classes

5, 42

Filing date

11/07/2023

Registration date

11/04/2025

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/04/2025

Last transaction

06/19/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

84

Owner location

CH

Examiner

BROWN, TINA

Law office

M90

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

APHAIA PHARMA AG
APHAIA IP AG

Representatives

David H. Siegel Norris McLaughlin, P.A.

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations for the treatment of metabolic diseases, vascular diseases, neurodegenerative diseases, skeletal diseases, mental disorders and gastroenterological diseases; pharmaceutical preparations for the prevention of metabolic diseases, vascular diseases, neurodegenerative diseases, skeletal diseases, mental disorders and gastroenterological diseases; pharmaceutical preparations for the treatment of pre-diabetic conditions, insulin resistance, obesity, type 2 diabetes, metabolic syndrome, hyperlipidemia, non-alcoholic fatty liver steatohepatitis, non-alcoholic steatohepatitis, depression, motivational disorders, depressive moods and malabsorption disorders; pharmaceutical preparations for the prevention of pre-diabetic conditions, insulin resistance, obesity, type 2 diabetes, metabolic syndrome, hyperlipidemia, non-alcoholic fatty liver steatohepatitis, non-alcoholic steatohepatitis, depression, motivational disorders, depressive moods and malabsorption disorders; pharmaceutical preparations for improving mood and mental and physical wellbeing; food supplements and dietary preparations adapted for medical purposes for the treatment of metabolic diseases, vascular diseases, neurodegenerative diseases, skeletal diseases, psychic disorders and gastroenterological diseases; food supplements and dietary preparations adapted for medical purposes for the prevention of metabolic diseases, vascular diseases, neurodegenerative diseases, skeletal diseases, psychic disorders and gastroenterological diseases; food supplements and dietetic preparations adapted for medical purposes for the treatment of pre-diabetic states, insulin resistance, obesity, type 2 diabetes, metabolic syndrome, hyperlipidemia, non-alcoholic fatty liver steatohepatitis, depression, motivational disorders, depressed mood and malabsorption disorders; food supplements and dietetic preparations adapted for medical purposes for the prevention of pre-diabetic states, insulin resistance, obesity, type 2 diabetes, metabolic syndrome, hyperlipidemia, non-alcoholic fatty liver steatohepatitis, depression, motivational disorders, depressed mood and malabsorption disorders; food supplements and dietetic preparations adapted for medical purposes for improving mood and mental and physical well-being all of the foregoing excluding any goods that consist of, contain or are derived from cannabis, marijuana or hemp

Class 42

Pharmaceutical research and development services; biochemical research and development services; medical research and development services; all of the foregoing excluding services in relation to any goods that consist of, contain or are derived from cannabis, marijuana or hemp

Publications

History of USPTO decisions and trademark events.

32 publications found

NREP

NEW REPRESENTATIVE AT IB RECEIVED

06/18/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

05/28/2026

FICS

FINAL DISPOSITION NOTICE SENT TO IB

05/12/2026

FIMP

FINAL DISPOSITION PROCESSED

05/12/2026

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

02/04/2026

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

11/04/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

11/04/2025

CHLD

CHANGE OF OWNER RECEIVED FROM IB

10/02/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

09/16/2025

PUBO

PUBLISHED FOR OPPOSITION

09/16/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

09/10/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

08/13/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/12/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/12/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

08/12/2025

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

06/27/2025

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

06/10/2025

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

06/10/2025

RFNT

REFUSAL PROCESSED BY IB

04/19/2025

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

03/28/2025

RFRR

REFUSAL PROCESSED BY MPU

03/28/2025

ATRV

ATTORNEY REVIEW COMPLETED

09/09/2024

LIME

LIMITATION FROM THE IB - REQUEST EXAM REVIEW

09/09/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

06/17/2024

CNRT

NON-FINAL ACTION WRITTEN

06/16/2024

DOCK

ASSIGNED TO EXAMINER

06/15/2024

LIME

LIMITATION FROM THE IB EXAMINED AND ENTERED

06/10/2024

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

05/26/2024

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

04/28/2024

MAFR

APPLICATION FILING RECEIPT MAILED

01/20/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/16/2024

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

01/11/2024

Continuous trademark protection

Get notified about every new filing that threatens APHAIA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.